University of California Irvine Medical Center, 101 The City Drive South, Building 53 Room 203, Orange, CA 92868, USA.
Stroke. 2012 Apr;43(4):1089-93. doi: 10.1161/STROKEAHA.111.635334. Epub 2012 Jan 26.
Organized systems of care have the potential to improve acute stroke care delivery. The current report describes the experience of implementing a county-wide system of spoke-and-hub stroke neurology receiving centers (SNRC) that incorporated several comprehensive stroke center recommendations.
Observational study of patients with suspected stroke of <5 hours duration transported by emergency medical system personnel to an SNRC during the first year of this system.
A total of 1360 patients with suspected stroke were evaluated at 9 hub SNRC, of which 553 (40.7%) had a discharge diagnosis of ischemic stroke. Of these 553, intravenous tissue-type plasminogen activator was administered to 110 patients (19.9% of ischemic strokes). Care at the 6 neurointerventional-ready SNRC was a major focus in which 25.1% (99/395) of the patients with ischemic stroke received acute intravenous or intra-arterial reperfusion therapy, and in which provision of such therapies was less common with milder stroke, older age, and Hispanic origin. The door-to-needle time for intravenous tissue-type plasminogen activator met the <60-minute target in only 25% of patients and was 37% longer (P=0.0001) when SNRC were neurointerventional-ready.
A stroke system that incorporates features of comprehensive stroke centers can be effectively implemented with substantial rates of acute reperfusion therapy administration. Experiences potentially useful to broader implementation of comprehensive stroke centers are considered.
有组织的医疗护理体系有改善急性脑卒中护理服务的潜力。本报告描述了实施全县范围的脑卒中神经学接收中心(SNRC)系统的经验,该系统整合了几个综合性脑卒中中心的建议。
对在该系统实施的第一年中,由紧急医疗系统人员运送至 SNRC 的、发病时间<5 小时的疑似脑卒中患者进行观察性研究。
共有 1360 名疑似脑卒中患者在 9 个脑卒中中心接受了评估,其中 553 名(40.7%)患者出院诊断为缺血性脑卒中。在这 553 名患者中,110 名(缺血性脑卒中的 19.9%)患者接受了静脉组织型纤溶酶原激活剂治疗。神经介入准备就绪的 6 个 SNRC 是重点关注对象,其中 25.1%(99/395)的缺血性脑卒中患者接受了急性静脉或动脉内再灌注治疗,而在神经介入准备就绪的情况下,脑卒中较轻、年龄较大和西班牙裔患者接受这种治疗的可能性较小。只有 25%的患者静脉注射组织型纤溶酶原激活剂的门到针时间达到<60 分钟的目标,且当 SNRC 为神经介入准备就绪时,该时间延长了 37%(P=0.0001)。
可以有效实施具有急性再灌注治疗实施率较高的脑卒中系统。考虑了更广泛实施综合性脑卒中中心的潜在有用经验。